Therapeutic use for a group of sulphated polysaccharides

Details Therapeutic use for a group of sulphated polysaccharides Therapeutic use for a group of sulphated polysaccharides

2005-02-11

2010-10-19

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S054000

Reexamination Certificate

active

07816329

ABSTRACT:
The present invention relates to the use of a sulphated polysaccharide in acid form or as a physiologically acceptable salt thereof, selected from the group constituting of inulin sulphate, gellan sulphate, pullulan sulphate, curdlan sulphate, alginiq acid sulphate, laminarin sulphate, and pectin sulphate, for the preparation of a medicament for the treatment or prophylaxis of arthrosis in a mammal. Preferably, the sulphated polysaccharide is inulin sulphate, most preferably inulin polysulphate sodium salt. The present invention also relates to the use of a sulphated oligosaccharide derived from a polysaccharide selected from the group consisting of inulin, gellan, pullulan, curdlan, alginic acid, laminarin, and pectin, for the preparation of a medicament for the treatment or prophylaxis of arthrosis in a mammal.

REFERENCES:
patent: 4021545 (1977-05-01), Nair et al.
patent: 4699900 (1987-10-01), Bayol et al.
patent: 5145841 (1992-09-01), Cullis-Hill et al.
patent: 2003/0181416 (2003-09-01), Comper
patent: 0 561 379 (1993-09-01), None
patent: WO-92/13541 (1992-08-01), None
patent: WO-02/36132 (2002-05-01), None
patent: WO-03/006645 (2003-01-01), None
patent: WO-2005/054446 (2005-06-01), None
Dictionary.com, 2002, p. 3.
Komai et al, International Journal of Biological Macromolecules, 2002, 30, 197-204.
The Merck Manual, 16th Edition, 1992, pp. 1338-1342.
Database CA Online!: Accession No. 1999-492587; Minami, S. et al., “Veterinary-clinical uses of curdlan sulfate,” XP002347885, Chemical Abstracts Service, Columbus, Ohio (1999).
Miyamoto, K. et al., “Novel plasma-separation dilayer gellan-gellan-sulfate adsorber for direct removal of extra domain A containing fibronectin from the blood of rheumatoid arthritis patients,” International Journal of Biological Macromolecules, vol. 30, No. 3-4, pp. 197-204 (2002).
Jordan, K.M. et al., EULAR Recommendations 2003: An Evidence Based Approach to the Management of Knee Osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT);Ann Rheum Dis. 2003; 62, 1145-1155.
Altman, R. et al., “Development of Criteria for the Classification and Reporting of Osteoarthritis”,Arthritis and Rheumatism, vol. 29, No. 8, Aug. 1986, pp. 1039-1049.
Klippel, John H. et al., “Osteoarthritis and Related Disorders”, Pheumatology, 2ndEd., 1997.
Lequesne, M., “Symptomatic Slow-Acting Drugs in Osteoarthritis: A Novel Therapeutic Concept?*”,Expansion Scientifique Francaise, 1994, 69-73.
Harris, Edward D., Rheumatoid Arthritis, “Pathophysiology and Implications of Therapy”,The New England Journal of Medicine, vol. 322, No. 18, May 3, 1990, pp. 1277-1289.
Hochberg, Marc C., “Adult and Juvenile Rheumatoid Arthritis: Current Epidemiologic Concepts”,Epidemiologic Reviews—The Johns Hopkins University School of Hygiene and Public Health, vol. 3, 1981, pp. 27-44.
Committee for Proprietary Medicinal Products (CPMP), “Points to Consider on Clinical Investigation of Medicinal Products Other than NSAIDS for Treatment of Rheumatoid Arthritis”,The European Agency for the Evaluation for Medicinal Products, London, Dec. 17, 2003.
Combe, Bernard et al., “Euler Recommendations for the Management of Early Arthritis: Report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)”,Ann Rheum Dis., ARD Online First, published Jan. 5, 2006, www.ard.bmjjournals.com, pp. 1-24.
Gust Verbruggen et al., “Influence of Polysulfated Polysaccharides on Aggrecans Synthesized by Differentiated Human Articular Chondrocytes”, The Journal of Rheumatology, 1999, 26:1663-1671.
Peter Ghosh, “The Pathobiology of Osteoarthritis and the Rationale for the Use of Pentosan Polysulfate for It's Treatment”, Seminars in Arthritis and Rheumatism, 1999, 28(4):211-267.

Affiliated with

Also associated with

Rating

Therapeutic use for a group of sulphated polysaccharides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic use for a group of sulphated polysaccharides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic use for a group of sulphated polysaccharides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4183898